Difficulties in Calculating Productivity Costs: Work Disability Associated with Borderline Personality Disorder  by van Asselt, Antoinette D.I. et al.
Difﬁculties in Calculating Productivity Costs:Work Disability
Associated with Borderline Personality Disorder
Antoinette D. I. van Asselt, MSc,1 Carmen D. Dirksen, PhD,1 Arnoud Arntz, PhD,2 Johan L. Severens, PhD1,3
1Department of Clinical Epidemiology and MTA, University Hospital Maastricht, Maastricht,The Netherlands; 2Department of Clinical
Psychological Science, Maastricht University, Maastricht,The Netherlands; 3Department. of Health Organization, Policy, and Economics,
CAPHRI Research Institute, Maastricht University, Maastricht,The Netherlands
ABSTRACT
Objectives: In trial-based analyses, the Human Capital
(HC) approach is currently applied alternately with and
without the incorporation of productivity costs for persons
who are work disabled at baseline of the trial. We call these
methods HC-extended (HCEXT) and HC-limited (HCLIM),
respectively. Aim of the paper is to compare productivity
costs according to HCEXT with HCLIM and the Friction Cost
(FC) method, in patients with Borderline Personality Disor-
der (BPD).
Methods: Data were obtained from a multicenter random-
ized trial in The Netherlands, comparing two types of
outpatient psychotherapy, Schema Focused Therapy (SFT,
n = 44) versus Transference Focused Psychotherapy (TFP,
n = 42) for BPD. Mean age was 31.7 for SFT and 29.5 for
TFP. A cost-interview was administered every three months
for three years, and once again after the fourth year. Produc-
tivity costs were calculated according to HCLIM, HCEXT and
FC. A nonparametric bootstrap resampling method was
performed.
Results: During the trial, the number of work-disabled
patients increased for both treatments. Total productivity
costs for HCEXT were higher than for HCLIM and FC. In
addition, the incremental bootstrapped costs (TFP - SFT)
pointed in the same direction for HCLIM (€1168; 95% UI
€4700, €7563) and FC (€1206; -€2835, €4844), but turned
around for HCEXT(minus €1240; -€9973, €7911). None of the
increments were statistically signiﬁcantly different from zero.
Conclusions: The classical and frequently discussed contrast
between HC and FC is not the only difference when it con-
cerns productivity costs. Whether or not including produc-
tivity costs for patients who are work-disabled at baseline can
lead to contradictory conclusions.
Keywords: borderline personality, friction costs, human
capital, productivity costs, work disability.
Introduction
When performing an economic evaluation from the
societal perspective, the costs of lost productivity are a
relevant item in the analysis. However, the way that lost
productivity should be valued is still a point of dispute.
For the monetary valuation of lost productivity two
approaches can be distinguished. One option is the
Human Capital Approach (HC), which estimates the
value of all potentially lost production [1]. When a
person gets sick, disabled or dies, the resulting lost
productivity is valued by calculating the expected or
potential earnings lost, for which the actual gross earn-
ings of that person or, preferably, age- and sex- adjusted
standard wages are used. One of the basic principles of
the human capital method is the assumption that there
is full use of labor (i.e., no unemployment). The second
option is the FrictionCostMethod (FC), which assumes
that all sick, disabled, or deceased workers will eventu-
ally be replaced [2]. In FC, productivity costs are only
counted as long as it takes to replace someone. The
friction period is deﬁned as the time needed to restore
the initial production level. After this friction period,
costs to society fall back to zero. Apart from the costs
associated with lost production, the friction cost
method also includes, for instance, costs of recruiting
and training a new employee. The speed with which a
replacement can be found is dependent on the situation
on the labor market. In times of large unemployment,
the friction period is shorter than when the labor
market is very tense. So, the Human Capital approach
estimates the value of all potentially lost production,
whereas the Friction Cost method attempts to quantify
actual production losses. Furthermore, HC can also be
used to estimate productivity costs for nonpaid labor
(i.e., domestic activities, volunteer work, study). For
example, the Dutch guidelines advise to value the hours
of domestic activities lost against the wage rate of a
paid housekeeper. FC does not include an approach
to nonpaid activities, probably due to the fact that
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replacement is a less obvious option for domestic activi-
ties and volunteer work and not an option for study
activities. Of course, FC for paid work and HC for
nonpaid work can be used next to each other.
The differences between HC and FC have been
described extensively in previous research [3–13]. As is
to be expected, HC in general leads to higher produc-
tivity costs than FC. The younger the population, the
larger HC losses will be compared to FC, because of
the longer period over which productivity is lost. Also,
the difference between both methods will be larger in
cases of permanent disability and deaths, because HC
fully takes account of productivity costs in these cases
whereas FC only takes account of these costs for the
duration of the friction period.
Problem Deﬁnition
In trial based economic evaluations, the employment
status at baseline of the study is an important factor
for the way productivity losses are calculated. When
there is no employment at baseline (i.e., the patient is
on welfare or on unemployment beneﬁts), no produc-
tivity losses are counted. When a patient has a paid job
but is with sick leave at baseline, there are productivity
losses, but the magnitude depends on the method used
and the length of the period of sick leave. When a
patient is work disabled at baseline, it also depends on
the method used whether or not there are productivity
losses. When applying the FC method in The Nether-
lands, the friction period is typically treated as having
already passed at the moment that a person is declared
disabled for work, because ofﬁcial disability for work
is always preceded by a year of “normal” absence from
work. Of course, in other countries, this period of
normal absence preceding ofﬁcial disability might be
much shorter, even shorter than the friction period. In
that case, FC productivity costs are not necessarily
zero. It is also possible to be declared disabled for
work directly after leaving school or when on welfare.
In that case, productivity costs are zero, because that
person never had paid work. So, for the Dutch situa-
tion, according to FC in its current application, pro-
ductivity costs associated with work disability are zero
by deﬁnition. However, when studying trial-based eco-
nomic evaluations using HC, the way that work
disability-related costs at the start of the study are
valued is found to be rather indistinct. To the best of
our knowledge, in most randomized trials only pro-
ductivity costs of patients with paid employment at
baseline of the study [9,14–20] were calculated, imply-
ing that patients who were already disabled for work
at baseline were assigned zero productivity costs, even
though their disability might be caused by the disease
under study. Although strictly speaking, this method-
ology cannot be seen as an individual approach, as it is
merely a ﬂaw in the application of the HC in daily
practice, we will, for the sake of clarity, from now on
refer to this methodology as the HC limited approach:
HCLIM. In a number of cases, the publication did not
clearly reveal whether costs due to work disability at
baseline had been included in the calculation of
productivity costs [21–24]. Only in a minority of eco-
nomic evaluations costs of work disability at baseline
had actually been included in the estimation of pro-
ductivity costs [25–27]. We will refer to the latter as
the HC extended approach: HCEXT. So, the Human
Capital approach is often put into practice as HCLIM,
since in the majority of trial-based economic evalua-
tions disease-related work disability is not counted as
productivity costs when it already exists at the baseline
of a study. Summarizing, the discrepancy between the
two HC approaches and FC is twofold. First, when
absence lasts longer than the friction period a differ-
ence arises between HC in general and FC. Second,
when a person is disabled for work at baseline of a
study, a difference arises between HCLIM and FC on the
one hand and HCEXT on the other hand. To our knowl-
edge, there has been no previous research comparing
the different approaches for valuing work disability-
related productivity costs. Therefore, the aim of the
present paper is to investigate for paid work if, and
how much, productivity costs according to HCEXT on
the one hand differ from productivity costs according
to HCLIM and FC on the other hand, in a population
characterized by frequent disablement for work.
Borderline Personality Disorder
Individuals who suffer from borderline personality
disorder (BPD) constitute a very severe group of
psychiatric patients, who are difﬁcult to treat. The
problematic nature of BPD is characterized by re-
curring crises, hospitalizations, self-mutilation, sui-
cide attempts, addictions and episodes of depression,
anxiety and aggression. Also typical for BPD is its
chronic nature. The onset of BPD generally takes place
in adolescence, and prevalence in the general popula-
tion is estimated to be ranging from 0.5 to 2.0%
[28,29]. The suicide risk is estimated up to 10% [30].
From this description, it may be clear that BPD-
patients face many difﬁculties in completing an educa-
tion and in their professional life. In a cost-of-illness
study investigating the economic burden of BPD on
society, productivity costs, calculated with HCEXT,
accounted for almost 42% of total costs [31], a large
part of which was due to work disability.
A multicenter randomised trial was performed in
The Netherlands, comparing two types of outpatient
psychotherapy for 86 patients with BPD. The trial
compared schema focused therapy (SFT, n = 44) to
transference focused psychotherapy (TFP, n = 42)
over a period of four years. For details of the study,
see Giesen-Bloo et al. [32]. Alongside the RCT an
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economic evaluation was performed from the societal
perspective, including costs for lost productivity.
Methods
Data Collection
Data regarding occupational status and absence were
obtained by means of a face-to-face structured inter-
view performed by a research assistant. During the
trial, patients had an interview every 3 months over
3 years, and a ﬁnal follow-up interview after 4 years.
At each of the interviews, the use of resources since the
previous interview was recorded. In this way the entire
period from baseline to ﬁnal follow up was covered.
In total 14 interviews were administered, of which
the ﬁrst interview (the baseline interview) covered
3 months prior to start of the trial. Absence from work
was measured in days as well as hours.
Data Analysis
Baseline characteristics were tested for normality with
the Kolmogorov-Smirnov test. When data were dis-
tributed normally, a t-test was performed. In the case
of non-normality, a Mann–Whitney test was used for
variables with at least an ordinal scale. A Pearson
chi-square test was used for binary variables.
For the calculation of the costs of lost productivity,
hours of absence were used, and only BPD-related
absence from work was considered. The distinction
between what was BPD-related and what was not
BPD-related was made according to the opinion of the
patient. Data were analyzed using intention to treat,
for which missing cases (due to study dropouts) were
analyzed using the “last observation carried forward”
(LOCF) method. When a patient was full-time absent
from work at the last interview before dropout, the
LOCF was performed in such a way that after a year of
absence this patient was declared disabled for work.
Because the Dutch situation on disability for work
is rather complicated, we made some choices regarding
the analysis. For HCEXT, when a patient was on welfare
or unemployment beneﬁts at baseline, and switched to
work disablement during the course of the trial, this
patient was analyzed as work disabled throughout the
trial, since probably the nonproductive status at base-
line was already disease-related and only a matter of
inaccurate classiﬁcation by the social security authori-
ties. On the other hand, when a patient was work
disabled at baseline and moved over to welfare or
unemployment beneﬁts later in the trial (which was, in
practice, a very infrequent event), this was regarded as
a change in productivity, in the sense that work dis-
ablement was counted as productivity costs, and
welfare and unemployment were not. For an overview
of all assumptions used, see Table 1.
For FC, standardized FC tariffs as well as the friction
period of 154 days were obtained from the Dutch
Manual for Costing studies [33]. The tariffs are calcu-
lated based on the average value added per working
person. For HC both limited and extended approach,
standardized wages (adjusted for age and gender) were
used, also in accordance with common practice. Stan-
dardized wages were obtained from the Central Bureau
of Statistics [34]. FC tariffs and wages used are pre-
sented in Table 2. FC was calculated according to the
standards, implying that when a patient was continu-
ously absent for more than 154 days, it was assumed
that this patients’ place in the production process was
ﬁlled again and productivity returned to its original
level. Therefore, after these 154 days had passed, pro-
ductivity costs were zero. For patients who were absent
only a few hours per day or a few days per week
(part-time absence), it was assumed that there was no
replacement. In cases where a patient was with sick
leave at baseline of the study, but the period of absence
Table 1 Assumptions made
HCEXT HCLIM FC FC2
Welfare → disablement Work disabled Not included Not included Not included
Disablement → welfare Work disablement counted as
productivity costs, welfare
not
Not included Not included Not included
Part-time absence Productivity costs proportional Productivity costs
proportional
Productivity costs
proportional, no
replacement, i.e., friction
period does not end
Productivity costs
proportional, no
replacement, i.e., friction
period does not end
Sick leave at baseline, length
of period unknown
Productivity costs as usual Productivity costs as usual Friction period has already
passed
Friction period has
just started
Table 2 FC tariffs and HC standardized wages per hour in
euros, price level 2000
Age categories
Friction cost
method*
Human Capital
approach
Men Women Men Women
15–24 €19.04 €18.65 €8.57 €8.35
25–34 €30.43 €27.76 €14.50 €13.29
35–44 €37.97 €31.23 €18.05 €14.80
45–54 €42.17 €31.79 €20.27 €15.07
55–64 €44.44 €33.84 €21.21 €15.60
65 €44.44 €33.84 €15.23 €15.24
*Prices converted to 2000 level, adapted from Oostenbrink et al. [33]
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was unknown, it was assumed that the friction period
had already passed and productivity costs were set to
zero. In addition, we performed a sensitivity analysis in
which, for those patients with an unknown period of
absence at baseline, we assumed that the absence had
just started the day before the assessment, so they were
assigned a full friction period (see also Table 1).
For persons who were work-disabled at baseline,
including those who were declared work disabled after
leaving school, it was not known whether they had (or
would have had) a full-time or part-time job, or a job at
all. Therefore, to calculate HCEXT, we assigned them an
average job, in which part-time versus full-time propor-
tion and unemployment rates in the general population
were accounted for, ﬁtting age and sex of the person,
and counted the wages for these jobs as productivity
costs for the 4 years of the study. Part-time work-
disability was treated proportional. To calculate HCLIM,
only productivity costs for persons with a paid job at
baseline were counted. For comparability of results, the
80% elasticity of working hours in relation to produc-
tivity that is commonly used for FC was also used for
both HC approaches here. This 80% elasticity reﬂects
the fact that when people work less hours (for instance
as a consequence of illness), their production decreases
less than proportionate. In The Netherlands, the elas-
ticity has been found to be 80% [2], which implies that
when working hours decrease by 10%, productivity
only decreases by 8%.As the cost datawere skewed and
not normally distributed, a nonparametric bootstrap
resampling method with 1000 replications was used as
an alternative to the geometric mean [35,36]. Costs are
expressed in euros with the price level of the year 2000.
Results
Patient Characteristics
Patient characteristics are presented in Table 3. None
of the patient characteristics were statistically
signiﬁcantly different between TFP and SFT. All work
disablement cases were, at least partly, BPD-related.
Development in Work Disability
In Table 4, the switches in work disability status that
patients made during the trial are quantiﬁed. Figure 1
represents the proportion of work disabled patients
during the study for both treatment groups. The high
percentage of patients moving to work disablement in
the SFT-group is caused mainly by patients who were
already long-term absent at baseline and reached their
year of absence shortly after the start of the study.
Productivity Costs
Figure 2 shows the productivity costs for each mea-
surement according to FC, HCLIM and HCEXT for both
treatment arms, including the productivity costs at
baseline. FC2 represents the sensitivity analysis. HCEXT
clearly leads to higher productivity costs than both
HCLIM or FC at each measurement, whereas the differ-
ence in productivity costs between HCLIM and FC is less
pronounced. Table 5 shows the total productivity costs
over 4 years for SFT and TFP, excluding the produc-
tivity costs of the baseline measurement. Comparing
FC with HCLIM, total productivity losses valued with
FC are about €3000 lower for both TFP and SFT.
Although the hourly wage is much higher for FC, the
higher productivity costs of HCLIM were caused by
patients whose friction period had already passed at
baseline and patients who turned absent and/or dis-
abled for work after baseline. Both FC and HCLIM
indicate that the mean total productivity costs are
higher for TFP compared to SFT, although not statis-
tically signiﬁcant. When HCEXT is used instead
of HCLIM, in other words: when productivity costs
due to work disability at baseline are included, the
bootstrapped productivity costs increase with 237%
for TFP and 324% for SFT. Moreover, mean total
Table 3 Patient characteristics at baseline (interview)
TFP (n = 42) SFT (n = 44) P-value
Females (%) 40 (95%) 40 (91%) 0.434
Age (SD) 29.5 (6.5) 31.7 (8.9) 0.377
In paid employment (%) 22 (52%) 22 (50%) 0.825
Contract hours (SD) 341 (178) 284 (158) 0.281
(26 hours/week) (22 hours/week)
Fulltime (36 hours/ week) employment 9 (41%) 8 (36%) 0.707
(% from patients in paid employment)
Sick leave, fully or partly (% from patients in paid employment) 5 (23%) 6 (27%) 0.810
Sick leave > friction period 3 (14%) 3 (14%) 0.953
Unknown if sick leave > friction period 2 (9%) 3 (14%) 0.684
Hours of sick leave (SD) 140 (202) 126 (164) 0.813
On unemployment beneﬁts (%) 1 (2.4%) 2 (4.5%) 0.584
On welfare (%) 6 (14%) 6 (14%) 0.931
Receiving work disability beneﬁts (%) 18 (43%) 17 (39%) 0.690
Fully (80%) disabled (% from disabled patients) 16 (89%) 14 (82%) 0.581
Degree of disablement (SD) 95% (13.3) 89% (23.0) 0.508
Categories of occupational status are not mutually exclusive, meaning that a persons can be, for instance, both in paid employment and (partly) work disabled.
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productivity costs of TFP are now lower compared to
SFT, although, again, not statistically signiﬁcant. Pro-
ductivity costs of FC remain unchanged, because for
patients who are disabled for work at baseline, the
friction period by deﬁnition has passed. For the sensi-
tivity analysis (FC2), when we assign the persons with
an unknown period of absence at baseline a full fric-
tion period, total costs increase more for SFT, resulting
Table 4 Numbers of patients switching to and from work disablement (not disabled = paid job, absent from work or study, and not
receiving work disability beneﬁts), hours of absence, proportion of patients with absence, and number of patients reaching the friction
period of 154 days
Baseline Course of study At follow-up TFP (N = 42) SFT (N = 44)
Not disabled — Disabled 3 (7%) 7 (16%)
Not disabled Disabled Not disabled 1 (2%) 2 (5%)
Not disabled Not disabled Not disabled 16 (38%) 13 (30%)
Disabled — Not disabled 2 (5%) —
Disabled Not disabled Disabled 2 (5%) —
Disabled Disabled Disabled 14 (33%) 17 (39%)
Disabled Welfare/unemployed* Disabled — 1 (2%)
Welfare/unemployed Disabled† Not disabled 1 (2%) —
Welfare/unemployed Disabled† Disabled — 4 (9%)
Total mean hours of absence (SD) 208 (552) 188 (529)
Proportion of patients having absence 50% 43%
Number of patients reaching friction period 1 2
Only the most frequent and relevant switches are speciﬁed. Numbers can be deviant from Table 3, since persons in paid employment can also be (partly) work disabled. For this
table, these persons are classiﬁed as disabled.
*The welfare/unemployment was only partly. For HCEXT, this part is not counted as productivity costs. For HCLIM and FC, these patients are not included.
†For HCEXT, these patients are counted as being work disabled throughout the course of the study. For HCLIM and FC, these patients are not included.
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Figure 2 Productivity costs with and without work disability in time (all patients).
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in a lower increment between TFP and SFT, even lower
than for HCLIM.
Discussion
In agreement with previous studies, HCLIM resulted in
higher productivity losses than FC. For both FC and
HCLIM, productivity costs for TFP were higher than for
SFT, although not statistically signiﬁcant. Applying
HCEXT increased the total productivity costs in both
study arms considerably. In addition, productivity
costs for TFP now became lower compared to SFT.
Although none of the increments was statistically sig-
niﬁcantly different from zero, this case clearly shows
that the disparity between the methods regarding work
disability may lead to contradicting conclusions.
In cost-of-illness studies aimed at illustrating the
economic burden of disease on society, the costs of
disability for work are usually included when using
the Human Capital approach. However, in economic
evaluations it seems to be common practice in HC to
include only persons with a paid job at baseline for
calculation of productivity losses, i.e., to use HCLIM.
BPD leads to disease-related work disability for a
substantial part of the patients. So, if a therapy aimed
at curing or improving BPD has the effect that
patients will return to the workforce, this effect
should be quantiﬁed as savings (which are in fact a
decrease in productivity costs) in an economic evalu-
ation. Although not commonly applied, HC in theory
is able to do so and according to the principles of
HC, this should be done. The way that FC takes
account of patients returning to the workforce is
that, in the medium term, labor scarcity diminishes,
and the friction period shortens, with overall decreas-
ing productivity costs as a consequence [2]. Although
on a macroeconomic level this will correctly reﬂect
the events that have taken place, FC does not take
into consideration the short-term individual produc-
tivity gains of patients in a trial-based economic
evaluation.
So, there seems to be a discrepancy between the
standard in cost-of-illness studies, which includes the
costs of baseline work disability, and both the friction
cost method and HCLIM, which do not include these
costs. A cost-of-illness study involves an estimation of
the total economic burden which an illness poses on
society, and its main objective is to translate the burden
on society into monetary costs. Typically, in a cost-of-
illness study all costs associated with a particular
illness are identiﬁed and measured. Results of cost-
of-illness studies can be used to gain insight in how
much society is spending on a disease, and how much
potentially can be saved if effective therapy is offered.
Also, it identiﬁes the relative magnitude of the different
cost categories and the size of the contribution of each
sector in society. The information coming from cost-
of-illness studies can be helpful in setting priorities for
health care efﬁciency research [37–39]. So, when a
therapy is effective in reintegrating people to the work-
force, it would make sense to be able to quantify the
potential relief of this economic burden in an economic
evaluation. However, FC (at the microeconomic level)
and HCLIM fail to do this.
In addition, in an economic evaluation based on a
decision model, cost-of-illness studies might be used as
input. When cost-of-illness productivity estimates
(based on HCEXT) are the input for a modelling-based
economic evaluation, this only adds to the inconsis-
tency and confusion regarding the estimation of
productivity costs. Furthermore, for decision-making
based on results of economic evaluations, one should
be aware that not the absolute productivity costs
matter (which may indeed differ between HC and FC),
but the incremental productivity costs. Including the
costs associated with work disability in HCEXT did not
only inﬂuence the absolute productivity costs, but also
the incremental productivity costs in such a way that,
solely on the basis of productivity costs, TFP became
more favorable compared to SFT, because in the TFP
treatment group, more patients returned to the work-
force during treatment after being work disabled at
baseline. Although the differences were not statistically
signiﬁcant here, in cases where productivity costs con-
stitute a large part of the total societal costs, these
ﬁndings may have a substantial effect on the incremen-
tal cost-effectiveness ratio, and when bootstrap proce-
dures and cost-effectiveness acceptability curves [40]
are used for drawing conclusions, FC or HCLIM could
point in the opposite direction than HCEXT.
Table 5 Mean total productivity costs and bootstrapped mean (2.5th and 97.5th percentiles) per patient over 4 years
TFP SFT TFP-SFT
Mean Bootstrap Mean Bootstrap Mean Bootstrap
FC €3,999 €3,950 €2,667 €2,744 €1,332 €1,206
(9,276) (+1,644 +1,719) (10,082) (+429 +6,034) (-2,835 +4,844)
HCLIM €7,041 €7,135 €6,013 €5,967 €1,028 €1,168
(15,342) (+2,998 +11,994) (13,601) (+2,466 +10,400) (-4,700 +7,563)
HCEXT €24,042 €24,048 €25,261 €25,288 -€1,219 -€1,240
(23,180) (+17,495 +30,490) (22,592) (+19,071 +31,825) (-9,973 +7,911)
FC2 €4,343 €4,355 €3,366 €3,336 €977 €1,019
(9,678) (+1,716 +7,566) (10,409) (+964 +6,822) (-3,068 +4,952)
642 van Asselt et al.
In the present study, because of the limited time-
horizon, only few patients returned to work after work
disability. However, in the near future, it is to be
expected that more patients will start working again,
as both therapies have proven to be effective. Both FC,
and HCLIM for a large part, do not account for these
gains to society. Another difﬁculty in using FC and
HCLIM is that when a patient who was initially work
disabled starts working again and then turns absent
would cause productivity costs without ofﬁcially
having been productive. In the present analysis we
have not counted these costs, since we did not include
productivity costs for patients who were disabled at
baseline, but it is an interesting theoretical problem
which could be addressed in future research.
A limitation that should be noted is that, although
there were no signiﬁcantly different baseline imbal-
ances, the TFP patients worked 26 hours per week on
average, versus 22 hours for the SFT patients. This
could have had an impact on the results in the sense
that because the TFP patients worked more, they also
might have had more absence. Therefore, when we
would have corrected for this difference, the increment
between TFP and SFT for all three methods might have
been smaller. However, it is not to be expected that this
baseline difference of 4 hours per week had a notice-
able effect on the differences between the three
methods, since it is not related to the number of work
disabled patients at baseline.
Of course, it is possible to calculate the conse-
quences of using different approaches in a sensitivity
analysis. However, in the case of BPD, productivity
costs constitute a large part of the total societal costs,
so they may have a considerable impact on the cost-
effectiveness ratio. In general, for chronic diseases in
relatively young populations, like mental health disor-
ders, the way that costs associated with work disability
are valued can have a major inﬂuence on the outcome.
This statement holds especially in this population with
borderline personality disorder, of which a large part is
disabled for work, and where the disability is not
considered to be irreversible. So, variability in methods
to calculate productivity costs is actually a practical
problem, in the sense that using different costing
methods could lead to different policy conclusions.
Therefore, to adequately inform policymakers it is
relevant to have a reliable estimate, calculated by a
standardized method. The choice for using a certain
method is ﬁrst and foremost dependent on the theo-
retical background of the methods, i.e., does one want
to calculate macroeconomic (FC) or microeconomic
(HC) productivity costs? One could say that, to be
consistent with a societal perspective, one should take
into account the macroeconomic consequences of an
illness on the productivity level. However, there are
some practical problems involved in applying FC in
special cases such as we have outlined in this paper.
Therefore, it would be helpful if there were speciﬁc
instructions how to use FC in case of disabled persons
returning to the workforce. For instance, how can one
calculate the shortened friction period? For the time
being, because methods are still being developed [41]
researchers should be very explicit and elaborate about
the methods they use for calculating productivity costs.
We are grateful to all patients, research assistants, and thera-
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